MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
62.51
-0.43 (-0.68%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close62.94
Open62.74
Bid0.00 x 800
Ask0.00 x 1100
Day's Range62.24 - 62.94
52 Week Range52.83 - 66.41
Volume7,282,114
Avg. Volume9,900,187
Market Cap168.171B
Beta1.06
PE Ratio (TTM)108.52
EPS (TTM)0.58
Earnings DateJul 27, 2018
Forward Dividend & Yield1.92 (3.09%)
Ex-Dividend Date2018-06-14
1y Target Est69.44
Trade prices are not sourced from all markets
  • The Wall Street Journal4 hours ago

    [$$] Merck to Limit Drug-Price Increases, Cut Some Prices

    Merck & Co. said Thursday it will cut U.S. list prices for several of its drugs including the hepatitis C treatment Zepatier, and the company pledged to limit future net price increases. Merck, based in Kenilworth, N.J., said it was cutting prices “to help reduce patient out-of-pocket costs.” The price cuts will go into effect in the fall, a spokeswoman said.

  • Reuters9 hours ago

    Merck lowers prices of some drugs after Trump calls out industry

    Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers. Amid heightened political scrutiny over the high cost of prescription medicines and promises by Trump that drug price reductions were coming, New Jersey-based Merck became the first major drugmaker to announce voluntary price decreases. In addition to slashing the price of Zepatier, which owns a very small share of the hepatitis market, Merck said it would lower the list price by 10 percent of six other older drugs with minuscule sales.

  • MarketWatch12 hours ago

    Merck to lower price of Hep C treatment Zepatier by 60%, commits to 'responsible' pricing

    Merck & Co. Inc. (mrk) said Thursday it is adopting a 'responsible' pricing policy and will cut the prices of certain products, while committing to increasing the average price of its drugs by no more than the annual inflation rate. The high price of drugs has been a controversial topic in the last few years and one that President Donald Trump has pledged to address. Merck said it will reduce the price of its Zepatier treatment for Hepatitis C by 60%, and will lower other prices by 10%.

  • Business Wire12 hours ago

    Merck Reinforces Commitment to Responsible Pricing

    Merck (MRK), known as MSD outside the United States and Canada, has a long history of responsible pricing. In 2017, Merck issued its second annual Pricing Action Transparency Report, which showed that net prices across Merck’s U.S. product portfolio declined by 1.9 percent. The Merck products selected were based on a range of factors including the gap between list price and actual discounted (net) prices paid in the market, the contractual obligations under existing arrangements with payers, and the opportunity to broaden access to treatment.

  • Why Investors Are Excited about Advaxis
    Market Realist18 hours ago

    Why Investors Are Excited about Advaxis

    Advaxis (ADXS), in collaboration with Merck & Co. (MRK), is conducting a Phase 1 Part 2 trial to evaluate the safety and efficacy of ADXS-PSA as a monotherapy and in combination with Merck’s Keytruda in patients with previously treated metastatic, castration-resistant prostate cancer. In the trial, 13 patients were evaluated on monotherapy and 37 patients were evaluated on combination therapy. The safety profile was found to be consistent with prior clinical studies that used Lm Technology.

  • See what the IHS Markit Score report has to say about Merck & Co Inc.
    Markit19 hours ago

    See what the IHS Markit Score report has to say about Merck & Co Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. MRK credit default swap spreads are within the middle of their range for the last three years.

  • Investopedia4 days ago

    Analysis: Motivating Factors Behind Pfizer’s Big Split

    Pfizer, the worlds second largest pharmaceutical company, announced on Wednesday, July 11th, plans to split into three separate businesses in a major restructuring move. The Innovative Medicines division will bring in most of Pfizer’s revenue. In a press release, the company said that the growth potential for that business is strongest in part because of the aging population which will increase the demand for new medicines.

  • The Wall Street Journal4 days ago

    [$$] Startup Producing Cell-Grown Meat Raises New Funding

    and a top European meat processor are backing a startup producing beef from cattle cells, ramping up a race to transform the global meat industry with cell-culture technology. fuels a continuing effort to fulfill growing global demand for meat via a process that developers say requires a fraction of the resources used in traditional livestock and poultry production.

  • Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
    Zacks7 days ago

    Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

    Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

  • Dow 30 Stock Roundup: Boeing Q2 Commercial Deliveries Up Y/Y, Pfizer to Reorganize
    Zacks7 days ago

    Dow 30 Stock Roundup: Boeing Q2 Commercial Deliveries Up Y/Y, Pfizer to Reorganize

    The index enjoyed a strong week of gains, boosted by expectations of a strong second quarter earnings season.

  • Moody's7 days ago

    Merck Financial Services GmbH -- Moody's affirms Merck KGaA's Baa1 ratings

    Moody's Investors Service, ("Moody's") has today affirmed the Baa1 long-term issuer rating of Merck KGaA (Merck). Moody's has also affirmed the ratings of Merck's short term issuer, senior unsecured Medium Term Note program and junior subordinated ratings at P-2, (P)Baa1 and Baa3 respectively.

  • Merck's Keytruda Gets FDA's Priority Review for Liver Cancer
    Zacks8 days ago

    Merck's Keytruda Gets FDA's Priority Review for Liver Cancer

    The FDA grants a priority review to Merck's (MRK) label expansion filing for its key cancer drug Keytruda regarding the first-line treatment of advanced HCC.

  • Investopedia9 days ago

    Merck Stock Seen Rising 12% on Faster Profit Growth

    Merck & Co. Inc. ( MRK) shares have dramatically outperformed the S&P 500 this year, rising 10%. Those gains may be just the start. Analysts are looking for the stock to rise by nearly 12% higher to about $69. The analysts aren't the only ones all bulled up on the pharmaceutical company.

  • See what the IHS Markit Score report has to say about Merck & Co Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Merck & Co Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $375 million.

  • Fortune9 days ago

    After Trump Criticism, Pfizer Backtracks on Drug Price Hikes—For Now

    Trump is pleased with the result of his blast.

  • MarketWatch11 days ago

    Pfizer shares rise after President Trump attacks its drug price hikes

    President Donald Trump criticized pharmaceutical giant Pfizer Inc. (PFE) in a Monday tweet for recently increasing the prices of many of its prescription drugs. In the tweet, which referred to Pfizer and unspecified "others," Trump said that companies were "merely taking advantage of the poor & others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe & elsewhere. The presidential tweet follows a Financial Times report that Pfizer raised list prices for 100 products in early July, weeks after Trump promised large price reductions, and marking the second such increase this year for Pfizer.

  • Johnson & Johnson Stock Only Benefits from Big Moves That May Not Come
    InvestorPlace11 days ago

    Johnson & Johnson Stock Only Benefits from Big Moves That May Not Come

    One of the most often used arguments in favor of owning Johnson & Johnson (NYSE:JNJ) is its diversity. Diversification in and of itself doesn’t inherently make a company worth buying into, however. J&J has maintained its stature as one of the most recognizable names (if not the most recognizable name) in the healthcare arena.

  • See what the IHS Markit Score report has to say about Merck & Co Inc.
    Markit11 days ago

    See what the IHS Markit Score report has to say about Merck & Co Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $4.54 billion.

  • CNBC13 days ago

    Cramer's lightning round: Buy Merck on its superior anti-cancer portfolio

    Jim Cramer rattles off his take on callers' favorite stocks, including a drugmaker that's topping its competition.

  • InvestorPlace14 days ago

    Don’t Buy Biogen Stock on the Promise of an Alzheimer’s Breakthrough

    Biogen (NASDAQ:BIIB) is the hot stock of the moment thanks to success in a trial of an Alzheimer’s drug. Progress on Alzheimers makes Biogen stock worth at least a look, right? Both follow the so-called “amyloid hypothesis,” the idea that reducing amyloid plaques using monoclonal antibodies can reverse the disease.

  • Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
    Zacks14 days ago

    Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs

    Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.

  • InvestorPlace14 days ago

    Trade of the Day: Novocure Ltd (NVCR)

    To receive further updates on this Novocure Ltd (NASDAQ:NVCR) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today.

  • Dow 30 Stock Roundup: Bell-Boeing JV's Navy Deal Win, Merck Keytruda's Priority Review
    Zacks14 days ago

    Dow 30 Stock Roundup: Bell-Boeing JV's Navy Deal Win, Merck Keytruda's Priority Review

    The Dow traverses a holiday-shortened week during which trading volumes remain low.

  • Hitting cancer early - AstraZeneca's bid to outmanoeuvre rivals
    Reuters14 days ago

    Hitting cancer early - AstraZeneca's bid to outmanoeuvre rivals

    AstraZeneca (AZN.L) suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. Soriot and his team are increasingly confident that while AstraZeneca may have lost one part of the battle for cancer market dominance, it can still win elsewhere by targeting tumours before they have spread around the body. The idea that immunotherapy may actually work best in less sick patients is logical, since the immune system's natural role is to destroy nascent tumours.